Now showing items 11-15 of 15
Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma
Three days following administration of radioactive iodine in 38 patients, exposure rates such as dose rate close to the dress (D0), dose rate of dress at 1 m (D1), dose rate close to the bedsheet (B0), dose rate of bedsheet ...
Scintigraphic parameters with emphasis on perfusion appraisal in rest 99mTc-sestamibi SPECT in the recovery of myocardial function after thrombolytic therapy in patients with ST elevation myocardial infarction (STEMI)
Introduction: This study was performed to determine the clinical application of rest 99mTc-sestamibi in the assessment of viability and functional improvement of the left ventricle (LV) myocardium in the post-thrombolytic ...
Phase 2 study of a high dose of 186RE-HEDP for bone pain palliation in patients with widespread skeletal metastases
186Re-1-hydroxyethylidene-1,1-diphosphonate (HEDP) is an attractive radiopharmaceutical for the treatment of bone pain arising from skeletal metastatic lesions. Currently, 186Re-HEDP is most commonly used in European ...
One size does not fit all: The merit of absorbed doses to the blood in 131i therapy for differentiated thyroid carcinoma
The amount of 131I necessary for successful ablation in patients with differentiated thyroid cancer (DTC) is still subject to debate. This study investigates the relationship of the absorbed dose of radiation to the blood ...
Myocardial perfusion imaging using a technetium-99m Sestamibi in asymptomatic and low risk for coronary artery disease patients with diagnosed systemic lupus erythematosus
Introduction: The aim of the present study was to evaluate technetium-99m sestamibi single photon emission tomography (SPECT) myocardial perfusion imaging (MPI) and its association with some clinical and laboratory parameters ...